Cipla obtains FDA OK for generic Brovana
Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA.
Cipla has received the Food and Drug Administration’s blessing for arformoterol tartrate inhalation solution 15 mcg/2 ml.
The medication is the generic of Sunovion’s Brovana.
Brovana is a long-acting beta-2 adrenergic agonist (beta-2 agonist) indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Brovana had a market value of approximately $438 million for the 12-month period ending April 2021, according to IQVIA.
The product is available for shipping.